Filtered By:
Specialty: Drugs & Pharmacology
Condition: Hemorrhagic Stroke
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 692 results found since Jan 2013.
Circadian rhythm and risk of hemorrhagic transformation after acute ischemic stroke treated with intravenous thrombolysis - a systematic review
CONCLUSIONS: ICH occurred after ivT seems to follow a circadian pattern; the 18:00-00:00 time frame was the safest one, patients with AIS onset or ivT time between these hours had the lowest incidence of any ICH, including sICH. The 06:00-12:00 block was associated with the highest incidence of ICH and sICH. However, the analysis is limited by the small number of included studies and the heterogeneous findings reported. Further homogenized studies using comparable time frames and sICH definitions are needed to demonstrate this circadian pattern. The review protocol was registered in the OSF database under reference UHNF, d...
Source: CNS and Neurological Disorders Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Adina Stan Hanna Dragos Stefan Strilciuc Silvina Ilut Vitalie Vacaras Angela Cozma Paul Stefan Panaitescu Horatiu Stan Dafin F Muresanu Source Type: research
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research
Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: A non-inferiority meta-analysis of 6 randomised controlled trials
CONCLUSIONS: Compared with a combined treatment approach, thrombectomy alone was non-inferior at -10% non-inferiority margin, but not at a - 5% inferiority margin for functional independence. Current evidence cannot exclude clinically important differences between the two treatment approaches.PMID:37116733 | DOI:10.1016/j.vph.2023.107177
Source: Vascular Pharmacology - April 28, 2023 Category: Drugs & Pharmacology Authors: Lisa Christina Horvath Felix Bergmann Arthur Hosmann Stefan Greisenegger Kerstin Kammerer Bernd Jilma Jolanta M Siller-Matula Markus Zeitlinger Georg Gelbenegger Anselm Jorda Source Type: research
Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model
Publication date: Available online 30 March 2016 Source:Pharmacological Research Author(s): Yinzhong Ma, Li Li, Ziran Niu, Junke Song, Yihuang Lin, Huifang Zhang, Guanhua Du The treatment of acute ischemic stroke (AIS) using thrombolysis with recombinant tissue-plasminogen activator (rtPA, alteplase) is limited by its narrow time window and the risk of hemorrhage. Recombinant plasminogen activator (rPA, reteplase) has been used clinically on coronary artery thrombosis and acute myocardial infarction. It is necessary to induce strokes experimentally as a means of validating the rPA timing on patients with AIS. Howe...
Source: Pharmacological Research - March 30, 2016 Category: Drugs & Pharmacology Source Type: research
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation —a cohort study in primary care
ConclusionsIn this clinical setting, we found no evidence pointing to an increased risk of HS with antithrombotic treatment.
Source: European Journal of Clinical Pharmacology - November 7, 2016 Category: Drugs & Pharmacology Source Type: research
A therapeutic target of cerebral hemorrhagic stroke: matrix metalloproteinase-9.
This article reviews the role of MMP-9 in the pathogenesis of diseases such as brain hemorrhage, hemorrhagic transformation after cerebral infarction, subarachnoid hemorrhage, and brain injury.
PMID: 28460607 [PubMed - as supplied by publisher]
Source: Current Drug Targets - April 27, 2017 Category: Drugs & Pharmacology Authors: Dang B, Duan X, Wang Z, He W, Chen G Tags: Curr Drug Targets Source Type: research
Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case –Control Study
ConclusionOur study shows that the use of medications inhibiting serotonin and/or noradrenaline reuptake increases the risk of HS in patients aged 65 years and older and that the risk varies across individual ADs.
Source: Drug Safety - June 3, 2019 Category: Drugs & Pharmacology Source Type: research
Tirofiban for acute ischemic stroke: systematic review and meta-analysis
Conclusion Tirofiban seems to be safe in systemic treatment and may represent a potential choice for management of AIS. However, intra-arterial administration requires further adequately controlled studies in order to develop an appropriate protocol, similar to that in cardiology.
Source: European Journal of Clinical Pharmacology - January 2, 2020 Category: Drugs & Pharmacology Source Type: research
The perioperative complications and short-term death in endovascular treatment for acute stroke induced by extracranial carotid occlusion: a systematic review and a meta-analysis
CONCLUSIONS: EVT can effectively improve neurological function and reduce 90-day mortality for acute extracranial carotid occlusion patients without increasing the risk of symptomatic intracranial hemorrhage. Endovascular therapy is safe to perform from 6 to 24 hours after symptom onset.PMID:33755964 | DOI:10.26355/eurrev_202103_25259
Source: European Review for Medical and Pharmacological Sciences - March 23, 2021 Category: Drugs & Pharmacology Authors: G-M Cao J Hu H-L Dong Source Type: research
